国际医学
(000516)
| 流通市值：124.55亿 | | | 总市值：126.58亿 |
| 流通股本：22.24亿 | | | 总股本：22.60亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,606,256,924.42 | 2,420,461,714.17 | 1,172,923,244.52 | 4,617,873,479.43 |
| 营业收入 | 3,606,256,924.42 | 2,420,461,714.17 | 1,172,923,244.52 | 4,617,873,479.43 |
| 二、营业总成本 | 3,892,721,588.98 | 2,605,523,886.63 | 1,286,778,395.15 | 5,141,769,803.58 |
| 营业成本 | 3,274,876,374.7 | 2,190,858,912.92 | 1,081,008,638.98 | 4,177,035,768.63 |
| 税金及附加 | 47,322,428.77 | 31,748,108.61 | 16,259,100.47 | 70,209,297.41 |
| 销售费用 | 19,025,093.8 | 11,459,986.38 | 611,800.83 | 41,427,674.82 |
| 管理费用 | 415,587,071.07 | 278,901,980.11 | 143,489,452.4 | 627,978,220.14 |
| 研发费用 | 5,715,774.18 | 3,915,876.69 | 1,944,059.66 | 9,811,517.85 |
| 财务费用 | 130,194,846.46 | 88,639,021.92 | 43,465,342.81 | 215,307,324.73 |
| 其中:利息费用 | 130,933,373 | 90,621,009.43 | 45,969,808.24 | 219,033,108.83 |
| 其中:利息收入 | 6,228,860.17 | 5,495,859.92 | 4,546,172.89 | 9,502,772.05 |
| 加:公允价值变动收益 | -7,902,134.7 | -38,213,691.42 | -17,634,121.31 | 2,102,469.52 |
| 加:投资收益 | -1,003,915.95 | -670,272.92 | -327,052.85 | 71,762,260.79 |
| 资产处置收益 | 303,928.99 | 304,499.79 | - | 1,950,645.6 |
| 信用减值损失(新) | -3,543,284.95 | -478,050.72 | 678,248.16 | -21,676,516.18 |
| 其他收益 | 15,203,655.54 | 3,054,678.6 | 2,693,150.54 | 7,735,425.88 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -283,406,415.63 | -221,065,009.13 | -128,444,926.09 | -462,022,038.54 |
| 加:营业外收入 | 617,062.66 | 257,213.99 | 219,130.17 | 2,055,763.01 |
| 减:营业外支出 | 694,555.7 | - | 256,107.02 | 7,288,085.11 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -283,483,908.67 | -220,807,795.14 | -128,481,902.94 | -467,254,360.64 |
| 减:所得税费用 | 10,788,863.23 | 8,017,011.94 | 3,395,197.98 | 4,694,444.63 |
| 六、净利润 | -294,272,771.9 | -228,824,807.08 | -131,877,100.92 | -471,948,805.27 |
| 持续经营净利润 | -294,272,771.9 | -228,824,807.08 | -131,877,100.92 | -554,893,656.69 |
| 终止经营净利润 | - | - | - | 82,944,851.42 |
| 归属于母公司股东的净利润 | -212,108,983.83 | -173,605,843.66 | -104,912,277.28 | -368,360,645.24 |
| 少数股东损益 | -82,163,788.07 | -55,218,963.42 | -26,964,823.64 | -103,588,160.03 |
| (一)基本每股收益 | -0.1 | -0.08 | -0.05 | -0.16 |
| (二)稀释每股收益 | -0.1 | -0.08 | -0.05 | -0.16 |
| 九、综合收益总额 | -294,272,771.9 | -228,824,807.08 | -131,877,100.92 | -471,948,805.27 |
| 归属于母公司股东的综合收益总额 | -212,108,983.83 | -173,605,843.66 | -104,912,277.28 | -368,360,645.24 |
| 归属于少数股东的综合收益总额 | -82,163,788.07 | -55,218,963.42 | -26,964,823.64 | -103,588,160.03 |
| 公告日期 | 2024-10-25 | 2024-08-28 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |